JP2022540079A5 - - Google Patents

Info

Publication number
JP2022540079A5
JP2022540079A5 JP2022500004A JP2022500004A JP2022540079A5 JP 2022540079 A5 JP2022540079 A5 JP 2022540079A5 JP 2022500004 A JP2022500004 A JP 2022500004A JP 2022500004 A JP2022500004 A JP 2022500004A JP 2022540079 A5 JP2022540079 A5 JP 2022540079A5
Authority
JP
Japan
Prior art keywords
sequence
seq
chain variable
variable region
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022500004A
Other languages
English (en)
Japanese (ja)
Other versions
JP7658946B2 (ja
JP2022540079A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041228 external-priority patent/WO2021007338A1/en
Publication of JP2022540079A publication Critical patent/JP2022540079A/ja
Publication of JP2022540079A5 publication Critical patent/JP2022540079A5/ja
Priority to JP2025052993A priority Critical patent/JP2025111457A/ja
Application granted granted Critical
Publication of JP7658946B2 publication Critical patent/JP7658946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500004A 2019-07-08 2020-07-08 カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 Active JP7658946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025052993A JP2025111457A (ja) 2019-07-08 2025-03-27 カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871565P 2019-07-08 2019-07-08
US62/871,565 2019-07-08
PCT/US2020/041228 WO2021007338A1 (en) 2019-07-08 2020-07-08 Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025052993A Division JP2025111457A (ja) 2019-07-08 2025-03-27 カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法

Publications (3)

Publication Number Publication Date
JP2022540079A JP2022540079A (ja) 2022-09-14
JP2022540079A5 true JP2022540079A5 (enExample) 2023-07-18
JP7658946B2 JP7658946B2 (ja) 2025-04-08

Family

ID=71944318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500004A Active JP7658946B2 (ja) 2019-07-08 2020-07-08 カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法
JP2025052993A Pending JP2025111457A (ja) 2019-07-08 2025-03-27 カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025052993A Pending JP2025111457A (ja) 2019-07-08 2025-03-27 カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法

Country Status (6)

Country Link
US (1) US12377162B2 (enExample)
EP (1) EP3996816A1 (enExample)
JP (2) JP7658946B2 (enExample)
CN (2) CN119874926A (enExample)
CA (1) CA3145301A1 (enExample)
WO (1) WO2021007338A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093295A1 (en) 2018-03-06 2019-09-12 Imcare Biotech, Llc Serine protease inhibitor kazal (spik) compositions and methods
CA3145301A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
JP2022547574A (ja) * 2019-09-11 2022-11-14 インケア バイオテック， エルエルシー 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
US20250369960A1 (en) * 2022-06-30 2025-12-04 Allonnia, Llc Per- and polyfluorinated alkyl compound (pfas) binding proteins and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JP3469580B2 (ja) 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP2005511627A (ja) 2001-11-20 2005-04-28 シアトル ジェネティクス，インコーポレーテッド 抗ｃｄ３０抗体を使用する免疫学的疾患の治療
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
AU2008316224A1 (en) 2007-10-25 2009-04-30 Viventia Biotechnologies Inc. Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
US20110206697A1 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
CN104994875B (zh) * 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3087166A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
CA3093295A1 (en) * 2018-03-06 2019-09-12 Imcare Biotech, Llc Serine protease inhibitor kazal (spik) compositions and methods
CN109678950B (zh) * 2019-01-08 2022-05-10 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
CA3145301A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
JP2022547574A (ja) * 2019-09-11 2022-11-14 インケア バイオテック， エルエルシー 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
BR112022020753A2 (pt) 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau

Similar Documents

Publication Publication Date Title
JP2025111457A5 (enExample)
JP2022115986A5 (enExample)
JP2020526478A5 (enExample)
JP2009541204A5 (enExample)
JP2021500916A5 (enExample)
JP2015529202A5 (enExample)
JP2020516603A5 (enExample)
JP6081699B2 (ja) Ｉｌ−２８ｂの分析方法
US12553893B2 (en) Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use
RU2016116773A (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
JP2021501579A5 (enExample)
JP2018525320A5 (enExample)
JP2018515071A5 (enExample)
JP2019504013A5 (enExample)
To et al. False-positive SARS-CoV-2 serology in 3 children with Kawasaki disease
JP2018527895A5 (enExample)
JP2020189843A5 (enExample)
JP2021515597A5 (enExample)
JP2018520127A5 (enExample)
JP2021155416A5 (enExample)
RU2019132201A (ru) Антитела к человеческому эритроферрону и их применение
CA3168348C (en) Specific monoclonal antibodies to the human metapneumovirus (HMPV) antigen M and their use in a diagnostic method
US20240118278A1 (en) Hbv diagnostic, prognostic, and therapeutic methods and products
CN115362258A (zh) 腺病毒的免疫测定方法及免疫测定器具
JP2018520366A5 (enExample)